WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
WuXi XDC collaboration-with-guru-to-launch-certificate-programs-in-sector'>Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform is drawing significant interest across the industry.
SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ('WuXi XDC', stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform. Earendil Labs is an AI-powered biotech company focused on researching and developing next-generation innovative biologics for the treatment of autoimmune diseases, cancer, and other conditions with unmet medical needs. This collaboration marks the establishment of a robust strategic partnership aimed at accelerating the development of next-generation ADCs by synergistically combining WuXi XDC's globally leading ADC technology platform with Earendil Labs' cutting-edge AI-driven antibody discovery and development capabilities to address significant unmet medical needs.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Suzlon Appoints Ajay Kapur as Group CEO
- Fuel & Families: Why Iran’s 'Sorry' To The Gulf Is A Double Win For India
- Arthur Hayes Says 'Longer Trump Lingers In Iran,' 'Higher' The Chances Of Bitcoin Surging: Here's Why
- Bridgewater-Raritan considering merger with neighboring school district
Source: Original →